ABSTRACT:

UTIs, which are also commonly referred to as urinary tract infections, are a common and sometimes reoccurring infection that can range from happening on their own to posing a severe risk to the health of the patient. This condition is characterized by the presence of pathogenic bacteria in the urinary canal or strictures. This is the defining characteristic of the disorder. Not only is this a widespread source of illness and death, but it is also a substantial contributor to the development of antibiotic resistance. It is estimated that Uropathogenic Escherichia coli (UPEC), Proteus mirabilis, Pseudomonas aeruginosa, Enterococcus faecalis, and Klebsiella pneumoniae are the most common forms of pathogenic bacteria that are responsible for urinary tract infections. Urinary tract infections are a public health concern that can be caused by so many different types of bacteria that are considered to be harmful. Some individuals are of the opinion that the majority of the financial burden that these diseases generate can be attributed to the high incidence rates and novel drug resistance that have been created by uropathogenic bacteria. This is a hypothesis that has been proposed by someone. 

REFERENCES :

1) Argemi X, Hansmann Y, Prola K, Prévost G. (2019) Coagulase-Negative Staphylococci Pathogenomics. Int J Mol Sci. 11;20(5)
2) Behzadi, P., Urbán, E., & Gajdács, M. (2020). Association between Biofilm-Production and Antibiotic Resistance in Uropathogenic Escherichia coli (UPEC): An In Vitro Study. Diseases (Basel, Switzerland), 8(2), 17. https://doi.org/10.3390/diseases8020017
3) Chapelle, C., Gaborit, B., Dumont, R., Dinh, A., & Vallée, M. (2021). Treatment of UTIs Due to Klebsiella pneumoniae Carbapenemase-Producers: How to Use New Antibiotic Drugs? A Narrative Review. Antibiotics (Basel, Switzerland), 10(11), 1332. 

https://doi.org/10.3390/antibiotics10111332
4) Chen, C. Y., Chen, Y. H., Lu, P. L., Lin, W. R., Chen, T. C., & Lin, C. Y. (2012). Proteus mirabilis urinary tract infection and bacteremia: risk factors, clinical presentation, and outcomes. Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi, 45(3), 228–236. https://doi.org/10.1016/j.jmii.2011.11.007
5) Codelia-Anjum, A., Lerner, L. B., Elterman, D., Zorn, K. C., Bhojani, N., & Chughtai, B. (2023). Enterococcal Urinary Tract Infections: A Review of the Pathogenicity, Epidemiology, and Treatment. Antibiotics (Basel, Switzerland), 12(4), 778. https://doi.org/10.3390/antibiotics12040778
6) Ehlers S, Merrill SA. Staphylococcus saprophyticus Infection. [Updated 2023 Jun 26]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK482367/
7) Epp, A., Larochelle, A., UROGYNAECOLOGY COMMITTEE, & FAMILY PHYSICIANS ADVISORY COMMITTEE (2010). Recurrent urinary tract infection. Journal of obstetrics and gynaecology Canada : JOGC = Journal d’obstetrique et gynecologie du Canada : JOGC, 32(11), 1082–1090. https://doi.org/10.1016/S1701-2163(16)34717-X
8) Flores-Mireles, A. L., Walker, J. N., Caparon, M., & Hultgren, S. J. (2015). Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nature reviews. Microbiology, 13(5), 269–284. https://doi.org/10.1038/nrmicro3432
9) Foxman B. (2014). Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk factors, and disease burden. Infectious disease clinics of North America, 28(1), 1–13. https://doi.org/10.1016/j.idc.2013.09.003
10) Hannan T. J., Totsika M., Mansfield K. J., Moore K. H., Schembri M. A., Hultgren S. J. (2012). Host-pathogen checkpoints and population bottlenecks in persistent and intracellular uropathogenic Escherichia coli bladder infection. FEMS Microbiol. Rev. 36, 616–648. 10.1111/j.1574-6976.2012.00339.x
11) Hashem YA, Abdelrahman KA, Aziz RK. (2021) Phenotype–Genotype Correlations and Distribution of Key Virulence Factors in Enterococcus faecalis Isolated from Patients with Urinary Tract Infections. Infect Drug Resist.;14:1713-1723
12) Karlowsky, J. A., Lagacé-Wiens, P. R., Simner, P. J., DeCorby, M. R., Adam, H. J., Walkty, A., Hoban, D. J., & Zhanel, G. G. (2011). Antimicrobial resistance in urinary tract pathogens in Canada from 2007 to 2009: CANWARD surveillance study. Antimicrobial agents and chemotherapy, 55(7), 3169–3175. https://doi.org/10.1128/AAC.00066-11
13) Klein, R. D., & Hultgren, S. J. (2020). Urinary tract infections: microbial pathogenesis, host-pathogen interactions and new treatment strategies. Nature reviews. Microbiology, 18(4), 211–226. https://doi.org/10.1038/s41579-020-0324-0
14) Laupland, K. B., Ross, T., Pitout, J. D., Church, D. L., & Gregson, D. B. (2007). Community-onset urinary tract infections: a population-based assessment. Infection, 35(3), 150–153. https://doi.org/10.1007/s15010-007-6180-2
15) Lin E, Bhusal Y, Horwitz D, Shelburne SA, Trautner BW. (2012) Overtreatment of Enterococcal Bacteriuria. Arch Intern Med. ;172(1):33–38. doi:10.1001/archinternmed.2011.565
16) Lockhart, S. R., Abramson, M. A., Beekmann, S. E., Gallagher, G., Riedel, S., Diekema, D. J., Quinn, J. P., & Doern, G. V. (2007). Antimicrobial resistance among Gram-negative bacilli causing infections in intensive care unit patients in the United States between 1993 and 2004. Journal of clinical microbiology, 45(10), 3352–3359. https://doi.org/10.1128/JCM.01284-07
17) Malmartel, A., & Ghasarossian, C. (2016). Epidemiology of urinary tract infections, bacterial species and resistances in primary care in France. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 35(3), 447–451. https://doi.org/10.1007/s10096-015-2560-1
18) Mittal, R., Aggarwal, S., Sharma, S., Chhibber, S., & Harjai, K. (2009). Urinary tract infections caused by Pseudomonas aeruginosa: a minireview. Journal of infection and public health, 2(3), 101–111. https://doi.org/10.1016/j.jiph.2009.08.003
19) Narten, M., Rosin, N., Schobert, M., & Tielen, P. (2012). Susceptibility of Pseudomonas aeruginosa urinary tract isolates and influence of urinary tract conditions on antibiotic tolerance. Current microbiology, 64(1), 7–16. https://doi.org/10.1007/s00284-011-0026-y
20) Natsis NE, Cohen PR. (2018) Coagulase-Negative Staphylococcus Skin and Soft Tissue Infections. Am J Clin Dermatol. ;19(5):671-677
21) Newman, J. N., Floyd, R. V., & Fothergill, J. L. (2022). Invasion and diversity in Pseudomonas aeruginosa urinary tract infections. Journal of medical microbiology, 71(3), 001458. https://doi.org/10.1099/jmm.0.001458
22) Riwu, K. H. P., Effendi, M. H., Rantam, F. A., Khairullah, A. R., & Widodo, A. (2022). A review: Virulence factors of Klebsiella pneumonia as emerging infection on the food chain. Veterinary world, 15(9), 2172–2179. https://doi.org/10.14202/vetworld.2022.2172-2179
23) Schaffer, J. N., & Pearson, M. M. (2015). Proteus mirabilis and Urinary Tract Infections. Microbiology spectrum, 3(5), 10.1128/microbiolspec.UTI-0017-2013. https://doi.org/10.1128/microbiolspec.UTI-0017-2013
24) Shimizu T., Sugihara T., Kamei J., Takeshima S., Kinoshita Y., Kuboet T., et al.. (2021). Predictive Factors and Management of Urinary Tract Infections After Kidney Transplantation: A Retrospective Cohort Study. Clin. Exp. Nephrol. 25, 200–206. doi: 10.1007/s10157-020-01974-w
25) Wei D.D, Chen K.Q, Wang L.H. Clinical and molecular characteristics of high virulent Klebsiella pneumonia in infection in intensive care unit. Chin. J. Nosocomiol. 2016;26(1):5056–5059.
26) Whelan, S., Lucey, B., & Finn, K. (2023). Uropathogenic Escherichia coli (UPEC)-Associated Urinary Tract Infections: The Molecular Basis for Challenges to Effective Treatment. Microorganisms, 11(9), 2169. https://doi.org/10.3390/microorganisms11092169